Trial of AstraZeneca coronavirus vaccine in children paused amid rare blood clots probe
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has launched a probe into a potential association with the jab.
Parents have been told to be in touch with the site where their child received the vaccine if they have concerns.
But the University of Oxford made clear that no problems had arisen within the trial itself.
It said, however, that it was waiting for the results of the MHRA review before it administered any more doses to children.
- Coronavirus news live: Latest AstraZeneca vaccine updates
- ‘Link’ between AstraZeneca vaccine and blood clots, EMA official says
- Are younger people at risk of blood clots linked to AstraZeneca vaccine?
- UK regulator ‘may restrict use of Oxford Covid vaccine in younger people’ amid blood clot fears
An Oxford University spokesperson said in a statement: “Whilst there are no safety concerns in the paediatric clinical trial, we await additional information from the MHRA on its review of rare cases of thrombosis/thrombocytopaenia that have been reported in adults, before giving any further vaccinations in the trial.”
They added that parents and children should continue to attend all scheduled visits “and can contact the trial sites if they have any questions".
Earlier, Boris Johnson defended the AstraZeneca vaccine during a visit to the pharmaceutical giant’s manufacturing plant in Macclesfield.
The prime minister praised the work of the MHRA, but said that when it came to the vaccine, the advice was “to keep going out there, get your jab, get your second jab”.
Speaking to The Independent, Dr Simon Clarke, associate professor in cellular microbiology at the University of Reading, said the UK could “afford to be cautious” in pausing a trial of the Oxford-AstraZeneca vaccine in children, because it has access to other jabs.